Cover Image
市場調查報告書

全球全身麻醉劑市場:成長,趨勢,預測

Global General Anesthesia Drugs Market - Growth, Trends, and Forecasts (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 391430
出版日期 內容資訊 英文 122 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球全身麻醉劑市場:成長,趨勢,預測 Global General Anesthesia Drugs Market - Growth, Trends, and Forecasts (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 122 Pages
簡介

本報告提供全球全身麻醉劑市場相關調查,提供市場趨勢與今後的成長預測,彙整各藥物,給藥途徑,各地區趨勢,及打入市場的主要企業簡介等資訊。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 主要推論

第5章 市場概要與產業趨勢

  • 波特五力分析

第6章 促進要素,阻礙要素,機會,課題分析

  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會
  • 課題

第7章 市場區隔

  • 各藥物
  • 各給藥途徑
    • 吸入
    • 注射

第8章 各地區市場市場區隔

  • 北美
  • 歐洲
  • 亞太地區
  • 中東·非洲
  • 南美

第9章 競爭環境

  • 新產品上市
  • 合併·收購
  • 協定,聯合,聯盟

第10章 企業簡介

第11章 投資的機會相關分析師預測

第12章 市場未來發展預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The European anesthetic drugs market accounted for USD 3,240 million in 2015 and USD 3,321 million in 2016. The market is expected to reach USD 3,710 million by 2021, growing at a CAGR of 2.3% during the forecast period of 2016 to 2021.

While the general anesthetic drugs induce a complete lack of sensation, local anesthetics drugs target only a specific region. Local anesthetics are much safer to use and also have fewer side-effects compared to general anesthetics.

The advancement in surgical procedures, increasing cosmetic and orthopedic surgeries and the high incidence of emergency surgical procedures and critical care are propelling the growth of the market. However, side-effects of general anesthetics, lack of skilled anesthesiologists and regulatory issues are turning out to be the restraints for the market.

The European anesthesia drugs market has been segmented by the type into general and local anesthetics. The general anesthetics segment is further subdivided into most-used and popular drugs. These include Sevoflurane, Propofol, Desflurane, Dexmedetomidine, Isoflurane, Midazolam and others. The segment on local anesthetics includes Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Oxethazaine, Prilocaine, Benzocaine and other local anesthetics. The segmentation based on the route of delivery includes inhalation and injection. Amongst general anesthetics, the market for Propofol is expected to dominate the market throughout the forecast period. Amongst local anesthetics, Ropivacaine is expected to dominate the market.

Geographically, the European market has been segmented into the UK, Germany, France, Italy, Spain, Scandinavia, BENELUX and Rest of Europe.

Some of the key players in the market are:

Abbott

Astra Zeneca

Baxter

Hospira

Roche

What the Report Offers

Market analysis for the European anesthetic drugs market, with region-specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the European anesthetic drugs market.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.

Table of Contents

1. Introduction

  • 1.1 Study deliverables
  • 1.2 Market definition
  • 1.3 Study assumptions

2. Research approach and methodology

  • 2.1 Introduction
  • 2.2 Analysis methodology
  • 2.3 Study timeline
  • 2.4 Study phases
    • 2.4.1 Secondary research
    • 2.4.2 Discussion guide
    • 2.4.3 Market engineering & econometric model
    • 2.4.4 Expert validation

3. Executive summary

4. Key inferences

5. Market overview and industry trends

  • 5.1 Current market scenario
  • 5.2 Porter's five forces
    • 5.2.1 Bargaining power of suppliers
    • 5.2.2 Bargaining power of consumers
    • 5.2.3 Threat to new entrants
    • 5.2.4 Threat to substitute products and services
    • 5.2.5 Competitive rivalry within the industry

6. Market drivers, restraints, challenges, and opportunities

  • 6.1 Market drivers
    • 6.1.1 Rising number of surgeries
    • 6.1.2 New approvals of anesthetic drugs
    • 6.1.3 Increase in number of cosmetic surgeries
  • 6.2 Market restraints
    • 6.2.1 Side effects of general anesthetics
    • 6.2.2 Lack of skilled anesthesiologists
    • 6.2.3 Regulatory issues
  • 6.3 Market opportunity
  • 6.4 Market challenge

7. Market segmentation

  • 7.1 By product
    • 7.1.1 General anesthetics
      • 7.1.1.1 Propofol
      • 7.1.1.2 Sevoflurane
      • 7.1.1.3 Desflurane
      • 7.1.1.4 Dexmedetomidine
      • 7.1.1.5 Remifentanil
      • 7.1.1.6 Midazolam
      • 7.1.1.7 Others
    • 7.1.2 Local anesthetics
      • 7.1.2.1 Bupivacaine
      • 7.1.2.2 Ropivacaine
      • 7.1.2.3 Lidocaine
      • 7.1.2.4 Chloroprocaine
      • 7.1.2.5 Oxethazaine
      • 7.1.2.6 Prilocaine
      • 7.1.2.7 Benzocaine
      • 7.1.2.8 Other local anesthetics
  • 7.2 By application
    • 7.2.1 General anesthetics
    • 7.2.2 Plastic Surgery
    • 7.2.3 Cosmetics
    • 7.2.4 Dental Anesthetics
    • 7.2.5 Spinal anesthetics
    • 7.2.6 Peripheral nerve block
    • 7.2.7 Epidural
    • 7.2.8 Interscalene block
    • 7.2.9 Saddle block
    • 7.2.10 Others
  • 7.3 By route of administration
    • 7.3.1 Inhalation
    • 7.3.2 Injection

8. Market segmentation by geography

  • 8.1 Europe
    • 8.1.1 Introduction
    • 8.1.2 Germany
    • 8.1.3 United Kingdom
    • 8.1.4 France
    • 8.1.5 Italy
    • 8.1.6 Spain
    • 8.1.7 Scandinavia
    • 8.1.8 BENELUX
    • 8.1.9 Rest of Europe

9. Competitive landscape

  • 9.1 Merger and acquisition analysis
  • 9.2 New product launches
  • 9.3 Agreements, collaborations, and partnerships

10. Company profiles

  • 10.1 Baxter
  • 10.2 Hospira
  • 10.3 Abbott
  • 10.4 Astra Zeneca
  • 10.5 Roche
  • 10.6 Novartis
  • 10.7 Pfizer
  • 10.8 Boehringer Ingelheim
  • 10.9 Eisai

11. Future outlook for investment opportunity

12. Analyst outlook of the market

Back to Top